Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lymphoma, Extranodal NK-T-Cell 2 Small Cell Lung Carcinoma 1 Recurrence 1 Radiation Pneumonitis 1 Pleural Effusion, Malignant 1 Neoplasm, Residual 1 NSCLC 1 Lung Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 11 Drug Therapy 9 aflutinib 8 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 Paclitaxel 5 icotinib 4 Vinorelbine 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × sugemalimab × Clear all

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Peking Union Medical College

Phase NA Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡